enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Moderate Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $23.00.

A number of equities research analysts have commented on the company. Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a report on Tuesday, November 11th. Morgan Stanley lifted their price objective on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. Jefferies Financial Group initiated coverage on shares of enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Finally, Citizens Jmp upped their price objective on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 12th.

Institutional Investors Weigh In On enGene

A number of large investors have recently modified their holdings of the stock. Cresset Asset Management LLC acquired a new stake in shares of enGene during the 2nd quarter valued at $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene during the second quarter worth $38,000. PFS Partners LLC purchased a new stake in shares of enGene during the third quarter valued at $61,000. Raymond James Financial Inc. lifted its holdings in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of enGene in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Up 7.8%

enGene stock opened at $9.55 on Wednesday. The stock has a market cap of $639.75 million, a PE ratio of -4.17 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. The stock’s fifty day moving average is $9.06 and its two-hundred day moving average is $7.21. enGene has a 1-year low of $2.65 and a 1-year high of $12.25.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). On average, sell-side analysts expect that enGene will post -1.56 EPS for the current fiscal year.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.